Physician profile
Amanda D Enos
NPI 1922683655
$5,026.00
in general payments reported to CMS, 2019-2025
30 companies · $861 in 2025
The $861 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $464 · 2022: $1,004 · 2023: $1,300 · 2024: $1,398 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,558.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,119.39 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,020.24 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $460.07 | 2022-2025 | Caplyta |
| Amgen INC. | $287.92 | 2024-2025 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $247.44 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $227.86 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $219.95 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $212.46 | 2021-2025 | |
| Boston Scientific Corporation | $202.97 | 2022 | |
| Sumitomo Pharma America, INC. | $114.27 | 2024-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.92 | 2022-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $107.14 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $100.38 | 2022 | |
| Exact Sciences Corporation | $79.92 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $79.78 | 2023-2024 | Veozah |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $41.51 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $40.59 | 2022 | |
| Alkermes, INC. | $40.05 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $38.65 | 2022 | |
| Merck Sharp & Dohme LLC | $36.09 | 2021-2022 | |
| Digestive Care, INC. | $31.16 | 2025 | Pertzye |
| Idorsia Pharmaceuticals US INC | $30.01 | 2023 | Quviviq |
| Nestle Healthcare Nutrition INC. | $28.45 | 2023 | |
| Echosens North America, INC. | $25.88 | 2024 | Fibroscan |
| Nevro Corp. | $23.12 | 2024 | Senza |
| Bayer Healthcare Pharmaceuticals INC. | $22.51 | 2024 | |
| Acadia Pharmaceuticals INC | $21.48 | 2024 | Daybue |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.56 | 2022 | |
| Eisai INC. | $19.28 | 2021 | |
| Amarin Pharma, INC. | $16.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Enos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.